Heineken Warns British Pubs Over GLP-1 Weight-Loss Drug Impact
Heineken urged British hospitality venues to adapt offerings as GLP-1 weight-loss medications potentially reduce beer consumption and revenue.
The brewer Heineken warned British pubs and bars to modify their offerings to counter potential revenue declines caused by the rising use of GLP-1 weight-loss medications, including Ozempic and Wegovy. In a company presentation, the brewer noted that these drugs can reduce the desire to drink and lead to fullness and fewer serves, which threatens traditional multi-pint drinking occasions.
To mitigate losses, Heineken advised hospitality venues to promote half-pints, small food pairings, and low- or no-alcohol beverages. The company stated it will continue to monitor these consumption behaviors into 2027, asserting that its portfolio is positioned to meet a shift toward premium and lower-alcohol products.
Other industry leaders have expressed skepticism or caution regarding the trend. Diageo informed investors that the impact should be manageable, while the Carlsberg Group stated that existing data does not yet support the view that GLP-1 drugs drive beer consumption trends. AB InBev declined to comment on the matter. However, market research from Circana indicates that households in the United States using GLP-1 drugs spent approximately 13.5% less on beer over a two-year period.
